French drugmaker Ipsen’s Cabometyx (cabozantinib ... use in England and Wales for previously treated advanced hepatocellular carcinoma (HCC), it has been announced. Those adult patients who ...

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

“It was encouraging to see that cabozantinib resulted in significant ... for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

according to a press release from the Dana-Farber Cancer Institute. The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with ...

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly. The ...

"Despite advances in recent years, there has remained a critical need for new and effective therapies for patients whose cancer has grown or spread. Cabozantinib significantly improved outcomes in ...

Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma ... royalty revenues for the sales of cabozantinib outside of the United States ...